https://beonemedaffairs.kinsta.cloud/7683/quick-reference-guide-for-hematological-malignancies/ 2025-04-29T12:31:27+00:00 https://beonemedaffairs.kinsta.cloud/7693/quick-reference-guide-for-solid-tumors/ 2025-04-29T13:05:20+00:00 https://beonemedaffairs.kinsta.cloud/8033/tislelizumab-molecule-overview/ 2025-05-23T13:28:15+00:00 https://beonemedaffairs.kinsta.cloud/8049/cdk4-moa/ 2025-05-23T13:29:06+00:00 https://beonemedaffairs.kinsta.cloud/7689/zanubrutinib-molecule-overview/ 2025-05-23T13:42:20+00:00 https://beonemedaffairs.kinsta.cloud/7699/sonrotoclax-molecule-overview/ 2025-05-23T13:42:59+00:00 https://beonemedaffairs.kinsta.cloud/7705/bgb-16673-molecule-overview/ 2025-05-23T13:43:32+00:00 https://beonemedaffairs.kinsta.cloud/7709/cdac-platform-moa/ 2025-05-23T13:44:53+00:00 https://beonemedaffairs.kinsta.cloud/7697/tislelizumab-moa-video/ 2025-05-23T13:46:43+00:00 https://beonemedaffairs.kinsta.cloud/7703/bgb-16673-moa/ 2025-05-23T14:20:28+00:00 https://beonemedaffairs.kinsta.cloud/7687/zanubrutinib-moa-video/ 2025-05-23T14:24:17+00:00 https://beonemedaffairs.kinsta.cloud/7681/btki-resistance-infographic/ 2025-05-23T14:24:56+00:00 https://beonemedaffairs.kinsta.cloud/8075/clinical-development-in-nsclc/ 2025-05-23T14:47:31+00:00 https://beonemedaffairs.kinsta.cloud/8077/rationale-305-factsheet/ 2025-05-23T14:56:14+00:00 https://beonemedaffairs.kinsta.cloud/8080/rationale-303-slide-kit/ 2025-05-23T15:23:01+00:00 https://beonemedaffairs.kinsta.cloud/8083/tislelizumab-in-escc-the-phase-3-rationale-302-trial/ 2025-05-23T15:24:57+00:00 https://beonemedaffairs.kinsta.cloud/8085/factsheet-bgb-3111-215/ 2025-05-23T15:27:28+00:00 https://beonemedaffairs.kinsta.cloud/8087/zanubrutinib-in-previously-treated-cll-sll-mcl-mzl-or-wm-intolerant-to-ibrutinib-acalabrutinib/ 2025-05-23T15:29:40+00:00 https://beonemedaffairs.kinsta.cloud/8089/factsheet-rosewood/ 2025-05-23T15:31:17+00:00 https://beonemedaffairs.kinsta.cloud/8091/zanubrutinib-in-follicular-lymphoma-the-phase-2-rosewood-trial/ 2025-05-23T15:34:13+00:00 https://beonemedaffairs.kinsta.cloud/8093/factsheet-magnolia/ 2025-05-23T15:37:58+00:00 https://beonemedaffairs.kinsta.cloud/8095/zanubrutinib-in-patients-with-relapsed-refractory-r-r-marginal-zone-lymphoma-mzl-the-phase-2-magnolia-trial/ 2025-05-23T15:39:49+00:00 https://beonemedaffairs.kinsta.cloud/8097/factsheet-zanubrutinib-in-patients-with-tn-cll-the-phase-3-sequoia-trial/ 2025-05-23T15:41:56+00:00 https://beonemedaffairs.kinsta.cloud/8099/zanubrutinib-in-tn-cll-the-phase-3-sequoia-trial/ 2025-05-23T15:43:55+00:00 https://beonemedaffairs.kinsta.cloud/8101/factsheet-zanubrutinib-vs-ibrutinib-in-r-r-cll-the-phase-3-alpine-trial/ 2025-05-23T15:45:53+00:00 https://beonemedaffairs.kinsta.cloud/8103/zanubrutinib-in-cll-sll-the-phase-3-alpine-trial/ 2025-05-23T15:48:35+00:00 https://beonemedaffairs.kinsta.cloud/8105/factsheet-aspen/ 2025-05-23T15:50:15+00:00 https://beonemedaffairs.kinsta.cloud/8118/zanubrutinib-in-waldenstroms-macroglobulinemia-the-phase-3-aspen-trial/ 2025-05-23T16:07:12+00:00 https://beonemedaffairs.kinsta.cloud/8249/fast-facts-for-hcps-waldenstrom-macroglobulinemia/ 2025-07-30T11:41:10+00:00 https://beonemedaffairs.kinsta.cloud/8247/fast-facts-chronic-lymphocytic-leukemia/ 2025-07-30T11:41:20+00:00 https://beonemedaffairs.kinsta.cloud/8245/fast-facts-marginal-zone-lymphoma/ 2025-07-30T11:41:28+00:00 https://beonemedaffairs.kinsta.cloud/8241/fast-facts-follicular-lymphoma/ 2025-07-30T11:41:37+00:00 https://beonemedaffairs.kinsta.cloud/8239/fast-facts-waldenstroms-macroglobulinemia-for-patients/ 2025-07-30T11:41:46+00:00 https://beonemedaffairs.kinsta.cloud/8237/fast-facts-chronic-lymphocytic-leukemia-for-patients/ 2025-07-30T11:41:56+00:00 https://beonemedaffairs.kinsta.cloud/8230/fast-facts-marginal-zone-lymphoma-for-patients/ 2025-07-30T11:42:05+00:00 https://beonemedaffairs.kinsta.cloud/8228/fast-facts-follicular-lymphoma-for-patients/ 2025-07-30T11:42:14+00:00 https://beonemedaffairs.kinsta.cloud/8576/slides-download-navigating-treatment-selection-and-infection-management-in-cll/ 2025-08-26T09:00:53+00:00 https://beonemedaffairs.kinsta.cloud/8549/satellite-symposium-btk-targeting-across-lymphomas-the-key-to-effective-treatment-today-and-tomorrow-download/ 2025-08-26T09:01:31+00:00 https://beonemedaffairs.kinsta.cloud/8743/tislelizumab-in-2l-treatment-of-advanced-or-metastatic-escc/ 2025-10-16T14:46:12+00:00 https://beonemedaffairs.kinsta.cloud/8746/tislelizumab-in-1l-treatment-of-advanced-or-metastatic-escc/ 2025-10-16T14:47:39+00:00 https://beonemedaffairs.kinsta.cloud/8749/tislelizumab-in-upper-gastrointestinal-cancers/ 2025-10-16T14:49:30+00:00 https://beonemedaffairs.kinsta.cloud/8752/tislelizumab-mode-of-action/ 2025-10-16T20:20:32+00:00 https://beonemedaffairs.kinsta.cloud/8755/ecp-symposium-tap-tumor-area-positivity-a-new-pd-l1-star-is-born/ 2025-10-30T13:06:22+00:00 https://beonemedaffairs.kinsta.cloud/8853/esmo-2025-what-are-the-latest-advances-and-key-challenges-in-first-line-io-treatment-of-es-sclc/ 2025-11-11T08:12:30+00:00 https://beonemedaffairs.kinsta.cloud/8855/esmo-2025-meeting-close/ 2025-11-11T08:12:30+00:00 https://beonemedaffairs.kinsta.cloud/8811/welcome-and-introductions/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8818/how-do-the-latest-data-in-resectable-nsclc-change-the-treatment-approach-for-our-patients/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8823/what-is-the-optimal-treatment-strategy-in-advanced-nsclc-by-pd-l1-expression-level/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8825/what-are-the-latest-advances-and-key-challenges-in-first-line-io-treatment-of-es-sclc/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8827/meeting-close/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8843/esmo-2025-looking-from-nsclc-to-sclc-whats-next-in-the-checkpoint-inhibitors-revolution/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8845/esmo-2025-welcome-and-introductions/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8847/esmo-2025-how-do-the-latest-data-in-resectable-nsclc-change-the-treatment-approach-for-our-patients/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8851/esmo-2025-what-is-the-optimal-treatment-strategy-in-advanced-nsclc-by-pd-l1-expression-level/ 2025-11-11T08:12:31+00:00 https://beonemedaffairs.kinsta.cloud/8882/tislelizumab-in-1l-treatment-of-advanced-g-gej-adenocarcinoma/ 2025-11-11T09:07:14+00:00